Central Lancashire Online Knowledge (CLoK)

Title	Can Filaments be stored as a shelf-item for on-demand manufacturing of oral 3D printed tablets? An initial stability assessment
Type	Article
URL	https://clok.uclan.ac.uk/id/eprint/37072/
DOI	https://doi.org/10.1016/j.ijpharm.2021.120442
Date	2021
Citation	Okwuosa, Tochukwu Chijioke, Sadia, Muzna, Isreb, Abdullah, Habashy, Rober, Peak, Matthew and Alhnan, Mohamed A (2021) Can Filaments be stored as a shelf-item for on-demand manufacturing of oral 3D printed tablets? An initial stability assessment. International Journal of Pharmaceutics, 600 (12044). ISSN 0378-5173
Creators	Okwuosa, Tochukwu Chijioke, Sadia, Muzna, Isreb, Abdullah, Habashy, Rober, Peak, Matthew and Alhnan, Mohamed A

It is advisable to refer to the publisher's version if you intend to cite from the work.
https://doi.org/10.1016/j.ijpharm.2021.120442

For information about Research at UCLan please go to http://www.uclan.ac.uk/research/

1 Research paper

2

3 **Can Filaments be stored as a shelf-item for on-demand**
4 **manufacturing of oral 3D printed tablets? An initial stability**
5 **assessment**

6

7

8

9 Tochukwu C Okwuosa [1,2], Muzna Sadia[1], Abdullah Isreb[1], Rober Habashy[1],
10 Matthew Peak[3] Mohamed A Alhnan[4]

11

12

13 *[1]School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, United Kingdom.*

14 *[2] School of Life and Medical Sciences, University of Hertfordshire, AL10 9AB Hatfield, United Kingdom.*

15 *[3]Paediatric Medicines Research Unit, Alder Hey Children's NHS Foundation Trust, Liverpool, UK*

16 *[4]Institute of Pharmaceutical Science, King's College London, London, United Kingdom.*

17

18

19

20 *Corresponding author at:
21 Institute of Pharmaceutical Sciences
22 King's College London
23 150 Stamford Street
24 London SE1 9NH. Tel.: +44 (0)20 7848 7265
Email: Alhnan@kcl.ac.uk
25
26

Abstract

3D printing of oral solid dosage forms is a recently introduced approach for dose personalisation. Fused deposition modelling (FDM) is one of the promising and heavily researched 3D printing techniques. However, the successful application of this technique relies greatly on the mass manufacturing of physically and chemically stable filaments, that can be readily available as a shelf item to be 3D printed on-demand. The stability of methacrylate polymers (Eudragit EPO, RL, L100-55 and S100), hydroxypropyl cellulose-SSL (HPC.SSL) and polyvinyl pyrrolidone (PVP)-based filaments over 6 months were investigated. Filaments manufactured by hot melt extrusion (HME) were stored at either 5 °C or 30 °C + 65 %RH with/without vacuuming. The effects of storage on their dimensions, visual appearance, thermal properties, and 'printability' were analysed. Theophylline content, as well as *in vitro* release from the 3D printed tablets were investigated. The filaments were analysed before storage, then after 1, 3 and 6 months from the manufacturing date.

Storing filaments at these conditions had a significant effect on their physical properties such as shape, dimensions, flexibility and hence compatibility with FDM 3D printing. The methacrylate-based filaments were more physically stable and more easily printed following storage. Owing to their hygroscopic nature, cellulose- and PVP-based filaments demonstrated a reduction in their glass transition temperature upon storage, leading to increased flexibility and incompatibility with FDM 3D printer. Theophylline contents was not significantly changed during the storage.

This work provides preliminary data for the impact of polymer species on the long-term stability of the filaments. In general, storage and packaging conditions have major impact on the potential of on-demand manufacturing of 3D printed tablets using hot melt extruded filaments.

1. Introduction

For many years, drug dosing for adults were based on the age and weight of the patient, with the dose for children extrapolated linearly from the former. The downside of such an approach is the lack of consideration of demographic, genetic, clinical and environmental factors which have been proven to contribute to population's variabilities (Cella et al. 2010). Hence, varied responses to therapy and susceptibility to adverse drug reactions have always been predominant issues (Al-Metwali and Mulla 2017; Nyboe Andersen et al. 2017). Dose personalisation, therefore, offers the advantage of tailoring doses to the patients' needs when required. With advancements in pharmacogenomics and wearable technologies, there is a rising interest in dose personalisation, in response to tested biomarkers, to achieve target pharmacodynamics and pharmacokinetics profiles.

A readily available dosing system will ensure efficient and safe dosing with minimal adverse effects when administered to patients. However, such an approach is mostly applicable currently for injectables, which allows easy dose adjustments (Patel et al. 2014). For this approach to be widely applied, a digital personalisation solution for commonly used dosage forms e.g. tablets should be developed. Dose adjustments are frequently achieved through the practice of tablet splitting. This approach is reported to introduce dosing inaccuracies (Habib et al. 2014), which could lead to underdosing, overdosing and severe toxicities with certain active pharmaceutical ingredients (APIs).

Different approaches are currently being investigated to personalise oral dosage forms, with 3D printing demonstrating significant potential (Isreb et al. 2019; Pereira et al. 2019; Tagami et al. 2019; Sen et al. 2020; Martinez et al. 2018). FDM has been heavily researched as an effective and accessible 3D printing technique. It offers several advantages such as the absence of a post-printing processing, in addition to its low-cost setup (Pereira et al. 2019; Sadia et al. 2018; Okwuosa et al. 2016). FDM 3D printing involves the use of filaments, usually manufactured by hot melt extrusion, as a pre-product, which are then fed into the heated nozzle of the FDM 3D printer (Pereira et al. 2019; Sadia et al. 2018; Okwuosa et al. 2016; Goyanes et al., 2014).

The potential of FDM 3D printing for on-demand manufacturing relies on producing stable, reproducible, dose-consistent and ready-to-use filaments. In order to effectively utilise this technique, these filaments should be easily mass-produced, packaged and stored before shipping to the printing sites, including hospitals and community pharmacies. This will enable the vision of producing 3D printed dosage forms that are intended to be dispensed shortly after being fabricated to match patients' needs in small batches to be achieved, and should maintain at least the stability standards for extemporaneous preparations. Therefore, the long-term stability of the filament, as a pre-product on the shelves of manufacturing units or compounding pharmacies, is of paramount importance for the success of this approach.

In the last six years, many studies have focused on the application of FDM 3D printing for dose personalisation (Charoenying et al. 2020; Eleftheriadis et al. 2019; Jamróz et al. 2020; Wei et al. 2020; Zhang et al. 2020; Fanous et al. 2020; Vo et al. 2020; Pereira et al. 2019; Sadia et al. 2018; Okwuosa et al. 2016; Pietrzak et al. 2015). However, there are little to no information about the long-term stability of these filaments. In fact, changes in the physicochemical properties of the filament during storage might not only compromise the efficacy of the active ingredient but may also affect its printability. Hence, adding more complexity to the technical challenges (Ilyés et al. 2019). For instance, a reduced plasticity of the filament upon storage will result in a brittle filament that may often break under pressure from the FDM 3D printer head gears (Ilyés et al. 2019, Nesereddin et al., 2018). Moreover, other changes in the filament diameter and/or shape may also have an impact on the final printed product, leading to variations in 3D printed tablets weights (weight uniformity) and in some cases the failure to complete the 3D printing process (Ilyés et al. 2019).

With many researchers working towards the adaptation of FDM 3D printing in pharmaceutical manufacturing, there is the need to study the stability of commonly used pharmaceutical polymers adapted to suit this novel manufacturing approach. In this work, the stability of HME-based filaments at 5 $^{\circ}$C or 30 $^{\circ}$C + 65 %RH were investigated. The impacts of the storage and packaging conditions were studied using theophylline as a model drug in combination with different model polymers. As the focus of this work is the impact of storage condition on physical change and the printability of different polymer-based filaments, a chemically stable molecule (Serajuddin, 1986), theophylline was selected as a model drug. The filaments in this study have been previously investigated to achieve immediate and modified release 3D printed structures using commercially available polymers of different chemical nature and hygroscopicity [PVP-based (Okwuosa et al. 2016), HPS.SSL-based (Pietrzak et al. 2015), L100-55-based, S100-based, RL-based and EPO-based filaments (Okwuosa et al. 2017; Sadia et al. 2018; Sadia et al. 2016)]. It is important to highlight that both Eudragit L100-55 and S100-based filaments were used to fabricate the shell in delayed release system and hence were made drug-free. The diameter, printability, thermal properties, physical form of the API, drug content of the filament, and the drug release profile of the 3D printed dosage forms were investigated before and after exposure to the storage conditions.

2. Materials and Methods

2.1 Materials

Hydroxypropyl cellulose (HPC.-SSL) was obtained from Nisso Chemical Europe (Dusseldorf, Germany). Theophylline was purchased from ACROS Organics. Polyvinylpyrrolidone (PVP, MW 40,000), triacetin and triethyl citrate (TEC) were purchased from Sigma-Aldrich (UK). Talc was purchased from Fluka Analytical (UK). Eudragit L100-55, RL, EPO and S100 were donated by Evonik Industries (Darmstadt, Germany).

2.2 Preparation of filaments

The PVP, HPC.-SSL and Eudragit based filaments were produced by HME following previously reported approach (Okwuosa et al. 2016). All filaments contained a model drug (theophylline) except for Eudragit L100-55 and S100 based filaments, which were used to 3D print the enteric layers (Okwuosa et al. 2017). The mixing and processing temperatures of the HME processes and nozzle sizes are detailed in **Table 1**.

2.3 Accelerated stability studies (storage conditions)

In order to determine the stability of the filaments over a long-term storage, accelerated stability studies were carried out according to the International Council for Harmonisation (ICH) guidelines [Q1A(R2)] (ICH, 2003). The drug loaded (PVP, HPC.SSL, Eudragit EPO and RL-based) and the drug free (Eudragit L100-55 and S100-based) filaments were sealed in polyvinyl chloride (PVC) polybags with or without vacuuming and stored in a fridge at 5 $^{\circ}$C or in an incubator at 30 $^{\circ}$C + 65 %RH. Vacuum sealing was achieved using Andrew James VS517 Dom Sealer. The filaments were characterised when freshly prepared and then after 1, 3 and 6 months of storage.

2.4 Filament dimension and visual appearance

In order to determine the effect of the storage conditions on the diameter of the filaments, changes in the diameter of the filaments were monitored using a Draper Electronic Digital caliper (0 – 25 mm) with a resolution of 0.001 mm. Filaments were observed to assess change in their visual appearance (change in shape, colour or presence of aggregation).

2.5 Printability test using FDM 3D printer

The 3D printing of the filaments that were stored under different conditions was attempted using the parameters detailed in **Table 1** to determine the effect of the storage conditions on 3D printing in comparison to a freshly prepared filament using Makerbot Experimental 2X 3D printer (Makerbot Inc, NY, USA). 3D Printing was carried out at a standard resolution (0.2 mm layer thickness) and a 100 % infill with rectilinear infill pattern. Other settings were set as previously detailed (Okwuosa et al.

148   2016). A caplet (L x W x H 10 x 4 x 3.6 mm) was designed and imported into the MakerWare software

149   Version 2.4.0.17 (Makerbot Industries, LLC., USA) and used to test the printability of the filaments.

150   The printed caplets weighed approximately 110 mg, containing approximately 11, 50, 50 and 52 mg of

151   theophylline for the PVP, HPC.SSL, Eudragit RL and EPO-based caplets respectively.

152   *2.6   Thermal gravimetric analysis (TGA)*

153

154   TGA analysis for the extruded filaments was carried out using a TGA Q500 (TA Instruments,

155   Hertfordshire, UK). The filaments were cut into small pieces (<1mm, approximately 10 mg) were

156   accurately weighed and placed in a 40 µL aluminium pan (TA Instruments, Hertfordshire, UK), which

157   was placed on a platinum pan. Samples were then scanned from 25 to 500 ºC at a heating rate of 10

158   ºC/min with a nitrogen purge of 40/60 mL/min for the sample and furnace, respectively. All

159   measurements were carried out in triplicates and the data analysed using a TA Universal Analysis 2000

160   software (TA Instruments, Hertfordshire, UK)

161   *2.7   Differential scanning calorimetry (DSC)*

162

163   For modulated temperature differential scanning calorimetry (MTDSC) analysis, a differential

164   scanning calorimeter (DSC) Q2000 (TA Instruments, Elstree, Hertfordshire, UK) was used. PVP-based

165   filaments were subjected to a modulated heat-cool-heat scan in order to measure and exclude the effect

166   of moisture content on the plasticity of the filaments. Eudragit L100-55 and S100-based filaments were

167   also subjected to a modulated scan. The modulation scan was applied using an amplitude of 0.212 °C

168   and a period of 40 sec, scanning from -70 to 200 °C at a heating rate of 2 °C/min.

169 As moisture did not interfere with the thermographs obtained unlike the aforementioned filaments, a

170 non-modulated standard scan was used for HPC.-SSL, Eudragit RL and EPO-based filaments from -50

171 to 300 °C at a heating rate of 10 °C/min. Analysis was carried out under a purge of nitrogen gas

172 (50 mL/min). All the data were analysed using a TA Universal Analysis 2000 software (TA

173 Instruments, Hertfordshire, UK). TA pin-holed standard lids and 40 µL aluminium pans (TA

174 Instruments, Hertfordshire, UK) were filled with approximately 5 mg sample and sealed. All

175 measurements were carried out in triplicates.

176

177   *2.8   X-ray powder diffractometry (XRPD)*

178

179   X-ray powder diffraction was carried out on the filaments over 6 months to investigate changes

180 in the physical forms of the API or excipients. This was assessed using a powder X-ray diffractometer,

181 D2 Phaser with Lynxeye (Bruker, Germany). Filaments were dipped in liquid nitrogen before crushing

182 them using a mortar and pestle. The powders were scanned from 2Theta (2θ) = 5° to 35° using 0.01

step and 1.25 sec count. The divergence slit was 1 mm and the scatter slit 0.6 mm. The wavelength of the X-ray was 0.154 nm using Cu source and a voltage of 30 kV and a current of 10 mA.

2.9   Determination of drug content (Eudragit EPO, RL, HPC.SSL and PVP-based filaments)

To determine changes in the drug contents of the filament after storage, 120 mg of the Eudragit EPO and RL, HPC.SSL and PVP-based filaments containing theophylline were solubilised in 0.1 M HCl and sonicated for 2h or 8 h (for Eudragit RL-based filament only). The API was measured by HPLC using an Agilent UV-HPLC 1260 series (Agilent Technologies, Inc., Germany) and an XTerra RP C18 column (150 × 4.6 mm, 5 μm particle size) (Waters, Ireland). A mobile phase of 10 mM solution of ammonium acetate buffer, methanol and acetonitrile at volume ratio of 86:7:7. Analysis was carried out at a wavelength of 272 nm, column temperature of 40 °C, flow rate of 1 mL/min, injection volume was 5 μL and a run time of 7 min as reported previously (Okwuosa et al. 2016).

2.10   In vitro drug release studies (Eudragit EPO and RL-based filament)

I*n vitro* drug release studies for the 3D printed tablets were carried out using a USP II dissolution apparatus (AT 7 Smart, Sotax, Switzerland). The tablets were tested in 900 mL of 0.1 M HCl solution for the EPO-based tablets for 2 hours. However, for the extended release formulation (Eudragit RL), dissolution testing was carried out in 750 mL of HCl solution, followed by the addition of 250 mL of 0.215 M tribasic phosphate buffer after 2hrs and the pH adjusted to 6.8. Samples were collected for another 6 hrs. The samples were automatically collected and analysed at 5 min intervals using a UV/VIS spectrophotometer (PG instruments limited, UK) at a wavelength of 272 nm. The path length used was 1 mm. The data were analysed using IDIS Software version 2.0 Automated Lab (Berkshire, UK).

2.11   Statistical analysis

One-way ANOVA was employed using SPSS Software (22.0.0.2) to analyse the results. the level of statistical significance was set at ($p < 0.05$).

3.   Results and discussions

The use of FDM 3D printing for on-demand dose personalisation relies greatly on the manufacturing of stable filaments that will be able to withstand storage and transportation. This ensures compatibility with the FDM 3D printer at the point of use, whilst maintaining the integrity of the loaded APIs and meeting the individual needs of patients. Therefore, the goal of this research was to investigate stability-related challenges that could be faced in the use of methacrylate, cellulose and polyvinyl pyrrolidone-based filaments for FDM 3D printing.

3.1   Physical and thermal properties of the stored filaments

Changes in the physical and thermal properties of these filaments due to storage could affect their 3D printing into solid dosage forms. Therefore, the impact of the storage conditions on the diameter of the filaments were investigated. It was observed that a filament diameter >1.8 mm will lead to blockage due to its inability to pass through the liquifying chamber of the FDM 3D printer's head. This is an essential quality criterion of the filaments to ensure consistent flow through the pressing gears into the hot nozzle. In addition, deformations in the cylindrical shape of the filament (deviation from the cylindrical shape) could potentially affect the filament interaction with the gears in the 3D printer, leading to inconsistency of the flow through the hot nozzle. Such effect can result in weight variation of the 3D printed product (data not included). These changes could also be influenced by the changes in the thermal properties of the filaments, with the TGA analysis being able to investigate water gain or loss and changes in the degradation profile of the stored filaments, with reference to the freshly prepared samples. Also, changes in the glass transition temperature (Tg) of the filament can significantly alter the mechanical properties of the filaments, in turn, the ability to load the filaments into the liquifying chamber of the FDM 3D printer head. Therefore, investigations into the effect of the storage conditions on the Tg of the filaments were also carried out using thermal method.

a)   Methacrylate-based filaments

Investigating the diameter of Eudragit EPO-based filaments after storage revealed that no change was noted when stored at 5 $^{\circ}$C. However, storing the filaments at 30 $^{\circ}$C + 65 %RH resulted in a permanent flattening/deformation of these filaments only when the storage bag was vacuum-sealed **(Table 2).** The resultant deformation affected its compatibility with the 3D printer and prevented its conversion into a solid dosage form. The TGA analysis of this filament demonstrated similar thermographs in the storage conditions (**Fig. 1A**) in comparison to a freshly prepared sample with insignificant moisture uptake with no observed wright loss between 50-150 $^{\circ}$C, a usual indication of water evaporation due to hygroscopicity. This non-hygroscopic nature of this polymer was also observed by Parikh *et al.* (2014) who recorded a0.2 %w/w moisture content. On the other hand, the DSC analysis revealed a slight reduction in the Tg of the filament due to storage (**Fig. 1B**). However,

245   this did not affect the printability of the filaments stored at 5 °C and 30 °C with no vacuuming. The

246   flattening of the vacuum-sealed filament when stored at 30 °C could be attributed to the increased

247   mobility of the polymeric chains above the Tg of the Eudragit EPO matrix. In addition, the negative

248   pressure on the filaments due to the vacuuming, may have also contributed to the deformation of the

249   filament. This was confirmed when a protective shell placed around the filaments, resulted in no

250   alteration in shape at the same storage conditions (data not included).

251   The Eudragit RL-based filament also lost its original cylindrical shape when stored in a vacuumed

252   PVC bag at 30 °C and 65 % RH, and hence was incompatible with the FDM 3D printer only at this

253   storage condition (**Table 2**). This was also the case for Eudragit L100-55–based filaments. Both

254   Eudragit based filaments demonstrated no changes in their weight loss TGA patterns due to storage as

255   well as no indication of water uptake (**Figs. 2A and 3A**). The filaments stored at 5 °C (with or without

256   vacuuming) and in a non-vacuumed bag at 30 °C + 65% RH were easily printed, demonstrating desirable

257   filament properties. An increase in Tg was observed, however, this had no effect on the filament's

258   printability (**Figs. 2B and 3B**) (Melocchi et al. 2020).

259   The dimensions of Eudragit S100-based filaments did not incur any significant changes due to

260   storage and maintained compatibility with the FDM 3D printer, irrespective of the storage condition

261   (**Table 2**). Their TGA thermographs remained similar during storage, demonstrating no water uptake

262   during the storage period (**Fig. 4A**). Unlike the previously discussed filaments, the S100-based

263   filaments demonstrated a higher Tg value (85-89 °C) (**Fig. 4B**), hence were unaffected by the storage

264   at 30 °C and the vacuuming pressure.

265   *b) Hydroxypropyl cellulose-based filaments*

266   The HPC-based filament deformed when stored in a vacuumed bag at 30 °C and 65% RH. In

267   addition, the filaments from other storage conditions were also incompatible with the FDM 3D printer.

268   The TGA analysis of the stored filaments showed weight gain values of 2.25 % and 2 %w/w for

269   filaments stored at 5 and 30 °C + 65% RH, respectively (**Fig. 5A**). This demonstrated the hygroscopic

270   nature of the cellulose-based matrix (Rowe et al. 2006). Water has often been reported to have a

271   plasticising effect on polymeric matrices (Teng et al. 2010), leading to a drop in the Tg of these

272   filaments from 36.7 to 34.9 °C after storage as demonstrated by DSC thermograph (**Fig. 5B**). This

273   confirms the potential role of water uptake as a major disruptor for compatibility with FDM 3D printing

274   process, due to increased flexibility. Such an increase will obstruct feeding into the liquifying chamber

275   of the FDM head, resulting in a poor grip of the gears on the filament and subsequently, the folding of

276   the filaments around the gears (Ilyés et al. 2019). This effect of high plasticity on the printability of the

277   filaments was also observed by Tan *et al.* (2020). As a result of these initial negative findings following

278   one-month storage, the HPC-based filaments were withdrawn from further studies.

c) Povidone-based filaments

280   Investigating the physical properties of the PVP-based filaments revealed their stability only at the

281   5 °C storage condition where they retained their shape and diameter. The TGA of freshly prepared PVP-

282   based filaments depicted an initial weight loss of approximately 4 % at around 120 °C due to moisture

283   loss, which could be attributed to the hygroscopic nature of PVP (Gupta et al. 2014). The storage of the

284   filaments at 5 °C resulted in up to 6.5 % water uptake (**Fig. 6**). PVP has been reported to be able to take

285   moisture up to 40% of its weight (Ramineni et al. 2013). It was not possible to determine precisely the

286   T_g of these filaments due to the excessive water evaporation upon heating, which interfered with the

287   detectability of the polymer's T_g. A heat-cool-heat DSC approach could eliminate these effects of

288   moisture. However, this approach led to the removal of moisture during the first heat scan and can mask

289   the potential of storage on T_g of the filament (**Supplementary Data, Fig. S1 and S2).** Such high water-

290   uptake was reported to produce a significant drop in its T_g (Fitzpatrick et al. 2002; Xie and Taylor 2017;

291   Teng et al. 2010). Although the filaments at 5 °C remained compatible with the 3D printer, their very

292   hygroscopic nature poses a major challenge to their application. Therefore, a future product would

293   require the use a specific packaging for these filaments to provide moisture-controlled environment.

294   This might have major implications on the cost and practicality of using these filaments for on-demand

295   use in the community and hospital pharmacies.

3.2   Impact of storage conditions on the physical form of theophylline

297   Changes in the physical forms of theophylline and excipients due to storage can influence the

298   drug release profile. Due to the degradation of methacrylate polymers when thermally scanned >170

299   °C (Parikh et al., 2016), it was not possible to use DSC to assess the physical form of theophylline

300   (melting point of 272 °C) To investigate this, XRPD was used to analyse the filaments before and after

301   storage. The Eudragit EPO, RL, HPC.SSL and PVP-based filaments loaded with theophylline revealed

302   the presence of diffraction peaks at $(2\theta) = 7$ and $12°$ (**Fig. 7**), which corresponds to theophylline crystals.

303   Talc, which was used as the structure forming agent, demonstrated sharp peaks at $(2\theta) = 9.52, 19.54,$

304     $28.87°$. The drug peaks indicated that a proportion of the API remained crystalline within the filament,

305   following thermal and mechanical stress of the HME processes (Huang and Dai 2014). This proved to

306   be dependent on the model drugs as previously investigated using these matrices (Okwuosa et al. 2016;

307   Sadia et al. 2016). The intensity peaks that corresponds to theophylline were also observed after storage,

308   indicating that a proportion of the API is in its crystalline form during these storage conditions.

309   However, the peak intensity at $(2\theta) = 12°$ due to theophylline was observed to increase for Eudragit

310   EPO-based filament whilst it decreased for the Eudragit RL-based filament over time (**Figs. 7A and**

311   **B**). Variations in peak intensity has been linked to crystalline concentrations (Siddiqui et al. 2015).

312   Also, it was reported that partial crystalline nature of matrices could alter due to storage (Lust et al.

313   2015; Huang and Dai 2014; Ueda et al. 2020). For filaments that did not include drug (Eudragit L100-

314 55 and S100), there were diffraction peaks at (2θ) = 9.52, 19.54, 28.87, which corresponds to the crystals

315 of talc, throughout the storage (**Supplementary Data, Figs. S3, S4, S5 and S6).**

3.3   Drug integrity and *in vitro* drug release

317 It was important that the integrity of the API-loaded in the filaments (Eudragit EPO, RL, HPC and

318 PVP-based) remains intact throughout the stability trial. This was important to ensure dosing accuracy

319 towards meeting the individual needs of patients using this novel manufacturing approach. HPLC

320 analysis showed no significant changes in API contents (**Supplementary Data, Table S1),** confirming

321 the stability of theophylline in the matrix.

322 Cellulose and the PVP-based filaments were deemed unstable and the L100-55 and S100-based

323 filaments were drugs-free, therefore, the dissolution testing for the tablets printed from these filaments

324 was not investigated. *In vitro* release study on the PVP-based matrices using USP II dissolution

325 apparatus demonstrated an increase in the rate of drug release with the aging of the filament (**Fig. 8**),

326 which was not as expected (Tian et al. 2014). The highly hygroscopic nature of PVP led to an increase

327 in moisture contents within the polymeric matrix. Drug mobility may also increase leading to phase

328 separation and further drug crystallisation (Chen et al. 2018).

329 Eudragit EPO is an immediate release polymer and as expected, the caplets from a freshly prepared

330 filament achieved more than 75 % theophylline release at 45 min. However, the rate of release slowed

331 down over time due to storage at 5 and 30 $^{\circ}$C + 65 %RH (**Fig. 9**). This could be due to crystalline growth

332 during storage at high temperature and humidity (Tian et al. 2014). This was observed in the XRPD

333 analysis of the filament with peak intensity due to theophylline increasing as the filament ages. It is also

334 possible that during storage, polymer relaxation led to the formation of denser matrix, leading to reduced

335 dissolution rate. Phase separation was observed in a solid dispersion of indometacin and Eudragit EPO

336 produced by HME, which decreased the dissolution rate of the active (Sarode et al. 2013).

337 On the other hand, Eudragit RL-based tablets showed a faster drug release after storage at 5 $^{\circ}$C in

338 comparison to the fresh sample (**Fig. 10**). A depression in peak intensity with aging was observed from

339 the XRPD studies, suggesting that more of the active became dissolved in the polymer over time.

340 Filaments stored at 30 $^{\circ}$C did not show a significant change in drug release compared to a freshly

341 prepared product. A solid dispersion containing Eudragit RL and indometacin demonstrated no

342 alteration in drug release after exposure to 40 $^{\circ}$C and 50 $^{\circ}$C for a short period of time (5 h) (Azarmi et

343 al. 2002).

344 In summary, we have

4. Conclusions

This work highlights some of the stability challenges facing HME based-filaments as a pre-product shelf item for on-demand use via FDM 3D printing. Storage conditions had a major impact on the physical properties of the filaments such as shape, dimensions, flexibility and hence compatibility with the FDM 3D printing. In comparison to the cellulose- and povidone-based filaments, methacrylate-based filaments (Eudragit EPO, RL, S100 and L100-55) were more generally physically stable and continued to be printable following storage. Polymers of lower Tg required specific storage conditions such as the use of a vacuumed container or fridge temperature. Filaments based on hygroscopic polymers (HPC and PVP) were more sensitive to Tg alterations due to water uptake, leading to 3D printing failures, and hence they were deemed less suitable to be used as a shelf-item product for on-demand printing. Overall, the integrity of the API in the drug loaded filaments was maintained.

This research provides a pioneering preview on the long-term stability consideration of pharmaceutical filaments. Further research is needed to confirm this trend with a wider range of polymers and to asses the impact of filament storage on the conforming of produced table batches with compendial criteria. For FDM 3D printing to be successfully adopted for on-demand manufacturing, more research on this important area is required.

362 **References**
363

364 Al-Metwali, B., and H. Mulla. 2017. "Personalised dosing of medicines for children." *J Pharm*
365   *Pharmacol* 69 (5): 514-524. https://doi.org/10.1111/jphp.12709.
366 Azarmi, S., J. Farid, A. Nokhodchi, S. M. Bahari-Saravi, and H. Valizadeh. 2002. "Thermal treating as a
367   tool for sustained release of indomethacin from Eudragit RS and RL matrices." *International*
368   *Journal of Pharmaceutics* 246 (1): 171-177. https://doi.org/https://doi.org/10.1016/S0378-
369   5173(02)00378-2.
370 Cella, Massimo, Catherijne Knibbe, Meindert Danhof, and Oscar Della Pasqua. 2010. "What is the right
371   dose for children?" *British journal of clinical pharmacology* 70 (4): 597-603.
372   https://doi.org/10.1111/j.1365-2125.2009.03591.x.
373 Charoenying, Thapakorn, Prasopchai Patrojanasophon, Tanasait Ngawhirunpat, Theerasak
374   Rojanarata, Prasert Akkaramongkolporn, and Praneet Opanasopit. 2020. "Three-dimensional
375   (3D)-printed devices composed of hydrophilic cap and hydrophobic body for improving
376   buoyancy and gastric retention of domperidone tablets." *European Journal of Pharmaceutical*
377   *Sciences* 155: 105555. https://doi.org/https://doi.org/10.1016/j.ejps.2020.105555.
378 Chen, Huijun, Yipshu Pui, Chengyu Liu, Zhen Chen, Ching-Chiang Su, Michael Hageman, Munir Hussain,
379   Roy Haskell, Kevin Stefanski, Kimberly Foster, Olafur Gudmundsson, and Feng Qian. 2018.
380   "Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular
381   Mechanism, Microstructure, and Its Impact on Dissolution Performance." *Journal of*
382   *Pharmaceutical Sciences* 107 (1): 317-326.
383   https://doi.org/https://doi.org/10.1016/j.xphs.2017.10.028.
384 Eleftheriadis, Georgios K., Christos Ritzoulis, Nikolaos Bouropoulos, Dimitrios Tzetzis, Dimitrios A.
385   Andreadis, Johan Boetker, Jukka Rantanen, and Dimitrios G. Fatouros. 2019. "Unidirectional
386   drug release from 3D printed mucoadhesive buccal films using FDM technology: In vitro and
387   ex vivo evaluation." *European Journal of Pharmaceutics and Biopharmaceutics* 144: 180-192.
388   https://doi.org/https://doi.org/10.1016/j.ejpb.2019.09.018.
389 Fanous, Marina, Sarah Gold, Stefan Hirsch, Joerg Ogorka, and Georgios Imanidis. 2020. "Development
390   of immediate release (IR) 3D-printed oral dosage forms with focus on industrial relevance."
391   *European Journal of Pharmaceutical Sciences* 155: 105558.
392   https://doi.org/https://doi.org/10.1016/j.ejps.2020.105558.
393 Fitzpatrick, Shaun, James F. McCabe, Catherine R. Petts, and Steven W. Booth. 2002. "Effect of
394   moisture on polyvinylpyrrolidone in accelerated stability testing." *International Journal of*
395   *Pharmaceutics* 246 (1): 143-151. https://doi.org/https://doi.org/10.1016/S0378-
396   5173(02)00375-7. http://www.sciencedirect.com/science/article/pii/S0378517302003757.
397 Goyanes, A., Buanz, A.B., Basit, A.W., Gaisford, S., 2014. Fused-filament 3D printing (3DP) for
398   fabrication of tablets. International journal of pharmaceutics 476, 88-92.
399

400 Gupta, Simerdeep Singh, Anuprabha Meena, Tapan Parikh, and Abu T.M. Serajuddin. 2014.
401   *Investigation of thermal and viscoelastic properties of polymers relevant to hot melt extrusion*
402   *- I: Polyvinylpyrrolidone and related polymers*. Vol. 5.
403 Habib, W. A., A. S. Alanizi, M. M. Abdelhamid, and F. K. Alanizi. 2014. "Accuracy of tablet splitting:
404   Comparison study between hand splitting and tablet cutter." *Saudi Pharm J* 22 (5): 454-9.
405   https://doi.org/10.1016/j.jsps.2013.12.014.
406 Huang, Yanbin, and Wei-Guo Dai. 2014. "Fundamental aspects of solid dispersion technology for
407   poorly soluble drugs." *Acta Pharmaceutica Sinica B* 4 (1): 18-25.
408   https://doi.org/https://doi.org/10.1016/j.apsb.2013.11.001.
409 Ilyés, Kinga, Norbert Krisztián Kovács, Attila Balogh, Enikő Borbás, Balázs Farkas, Tibor Casian, György
410   Marosi, Ioan Tomuță, and Zsombor Kristóf Nagy. 2019. "The applicability of pharmaceutical
411   polymeric blends for the fused deposition modelling (FDM) 3D technique: Material
412   considerations–printability–process modulation, with consecutive effects on in vitro release,

13

stability and degradation." *European Journal of Pharmaceutical Sciences* 129: 110-123. https://doi.org/https://doi.org/10.1016/j.ejps.2018.12.019.

ICH Harmonised Tripartite Guideline. 2003. "Stability Testing of New Drug Substances and Products Q1A(R2)."Accessed 31/12. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf.

Isreb, A., K. Baj, M. Wojsz, M. Isreb, M. Peak, and M. A. Alhnan. 2019. "3D printed oral theophylline doses with innovative 'radiator-like' design: Impact of polyethylene oxide (PEO) molecular weight." *Int J Pharm* 564: 98-105. https://doi.org/10.1016/j.ijpharm.2019.04.017.

Jamróz, Witold, Mateusz Kurek, Joanna Szafraniec-Szczęsny, Anna Czech, Karolina Gawlak, Justyna Knapik-Kowalczuk, Bartosz Leszczyński, Andrzej Wróbel, Marian Paluch, and Renata Jachowicz. 2020. "Speed it up, slow it down…An issue of bicalutamide release from 3D printed tablets." *European Journal of Pharmaceutical Sciences* 143: 105169. https://doi.org/https://doi.org/10.1016/j.ejps.2019.105169.

Lust, Andres, Clare J. Strachan, Peep Veski, Jaakko Aaltonen, Jyrki Heinämäki, Jouko Yliruusi, and Karin Kogermann. 2015. "Amorphous solid dispersions of piroxicam and Soluplus®: Qualitative and quantitative analysis of piroxicam recrystallization during storage." *International Journal of Pharmaceutics* 486 (1): 306-314. https://doi.org/https://doi.org/10.1016/j.ijpharm.2015.03.079.

Martinez, P. R., A. Goyanes, A. W. Basit, and S. Gaisford. 2018. "Influence of Geometry on the Drug Release Profiles of Stereolithographic (SLA) 3D-Printed Tablets." *AAPS PharmSciTech* 19 (8): 3355-3361. https://doi.org/10.1208/s12249-018-1075-3.

Melocchi, Alice, Marco Uboldi, Alessandra Maroni, Anastasia Foppoli, Luca Palugan, Lucia Zema, and Andrea Gazzaniga. 2020. "3D printing by fused deposition modeling of single- and multi-compartment hollow systems for oral delivery − A review." *International Journal of Pharmaceutics* 579: 119155. https://doi.org/https://doi.org/10.1016/j.ijpharm.2020.119155.

Nasereddin, J.M., Wellner, N., Alhijjaj, M., Belton, P., Qi, S., 2018. Development of a Simple Mechanical Screening Method for Predicting the Feedability of a Pharmaceutical FDM 3D Printing Filament. Pharm Res 35, 151.

Nyboe Andersen, A., S. M. Nelson, B. C. Fauser, J. A. García-Velasco, B. M. Klein, and J. C. Arce. 2017. "Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial." *Fertil Steril* 107 (2): 387-396.e4. https://doi.org/10.1016/j.fertnstert.2016.10.033.

Okwuosa, T.C., Pereira, B.C., Arafat, B., Cieszynska, M., Isreb, A., Alhnan, M.A., 2017. Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy. Pharm Res 34, 427-437.

Okwuosa, Tochukwu C., Dominika Stefaniak, Basel Arafat, Abdullah Isreb, Ka-Wai Wan, and Mohamed A. Alhnan. 2016. "A Lower Temperature FDM 3D Printing for the Manufacture of Patient-Specific Immediate Release Tablets." *Pharmaceutical Research* 33 (11): 2704-2712. https://doi.org/10.1007/s11095-016-1995-0. http://dx.doi.org/10.1007/s11095-016-1995-0.

Parikh, Tapan, Simerdeep Singh Gupta, Anuprabha Meena, and Abu Serajuddin. 2014. "Investigation of thermal and viscoelastic properties of polymers relevant to hot melt extrusion - III: Polymethacrylates and polymethacrylic acid based polymers." *Journal of Excipients and Food Chemicals* 5: 56-64.

Patel, J. N., B. H. O'Neil, A. M. Deal, J. G. Ibrahim, G. B. Sherrill, O. A. Olajide, P. M. Atluri, J. J. Inzerillo, C. H. Chay, H. L. McLeod, and C. M. Walko. 2014. "A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy." *Oncologist* 19 (9): 959-65. https://doi.org/10.1634/theoncologist.2014-0132.

Pereira, B. C., A. Isreb, R. T. Forbes, F. Dores, R. Habashy, J. B. Petit, M. A. Alhnan, and E. F. Oga. 2019. "'Temporary Plasticiser': A novel solution to fabricate 3D printed patient-centred cardiovascular 'Polypill' architectures." *Eur J Pharm Biopharm* 135: 94-103. https://doi.org/10.1016/j.ejpb.2018.12.009.

464   Pietrzak, K., A. Isreb, and M. A. Alhnan. 2015. "A flexible-dose dispenser for immediate and extended
465   release 3D printed tablets." *Eur J Pharm Biopharm* 96: 380-7.
466   https://doi.org/10.1016/j.ejpb.2015.07.027.
467   Ramineni, Sandeep K., Larry L. Cunningham, Thomas D. Dziubla, and David A. Puleo. 2013.
468   "COMPETING PROPERTIES OF MUCOADHESIVE FILMS DESIGNED FOR LOCALIZED DELIVERY OF
469   IMIQUIMOD." *Biomaterials science* 1 (7): 753-762. https://doi.org/10.1039/C3BM60064E.
470   Rowe, Raymond C., Paul J. Sheskey, and Siân C. Owen. 2006. *Handbook of pharmaceutical excipients*.
471   5th ed. Vol. Book, Whole. London: Pharmaceutical Press.
472   Sadia, M., A. Isreb, I. Abbadi, M. Isreb, D. Aziz, A. Selo, P. Timmins, and M. A. Alhnan. 2018. "From
473   'fixed dose combinations' to 'a dynamic dose combiner': 3D printed bi-layer antihypertensive
474   tablets." *Eur J Pharm Sci* 123: 484-494. https://doi.org/10.1016/j.ejps.2018.07.045.
475   Sadia, M., A. Sosnicka, B. Arafat, A. Isreb, W. Ahmed, A. Kelarakis, and M. A. Alhnan. 2016. "Adaptation
476   of pharmaceutical excipients to FDM 3D printing for the fabrication of patient-tailored
477   immediate release tablets." *Int J Pharm* 513 (1-2): 659-668.
478   https://doi.org/10.1016/j.ijpharm.2016.09.050.
479   Sarode, Ashish L., Harpreet Sandhu, Navnit Shah, Waseem Malick, and Hossein Zia. 2013. "Hot Melt
480   Extrusion for Amorphous Solid Dispersions: Temperature and Moisture Activated Drug–
481   Polymer Interactions for Enhanced Stability." *Molecular Pharmaceutics* 10 (10): 3665-3675.
482   https://doi.org/10.1021/mp400165b. https://doi.org/10.1021/mp400165b.
483   Sen, Koyel, Arushi Manchanda, Tanu Mehta, Anson W. K. Ma, and Bodhisattwa Chaudhuri. 2020.
484   "Formulation design for inkjet-based 3D printed tablets." *International Journal of
485   Pharmaceutics* 584: 119430. https://doi.org/https://doi.org/10.1016/j.ijpharm.2020.119430.
486   Serajuddin, A.T., 1986. Comparative thermal properties of the monohydrates of sodium theophylline
487   and theophylline. J Pharm Pharmacol 38, 93-96.
488   Siddiqui, A., Z. Rahman, M. Korang-Yeboah, and M. A. Khan. 2015. "Development and validation of X-
489   ray diffraction method for quantitative determination of crystallinity in warfarin sodium
490   products." *Int J Pharm* 493 (1-2): 1-6. https://doi.org/10.1016/j.ijpharm.2015.07.051.
491   Tagami, T., M. Ando, N. Nagata, E. Goto, N. Yoshimura, T. Takeuchi, T. Noda, and T. Ozeki. 2019.
492   "Fabrication of Naftopidil-Loaded Tablets Using a Semisolid Extrusion-Type 3D Printer and the
493   Characteristics of the Printed Hydrogel and Resulting Tablets." *J Pharm Sci* 108 (2): 907-913.
494   https://doi.org/10.1016/j.xphs.2018.08.026.
495   Tan, D. K., M. Maniruzzaman, and A. Nokhodchi. 2020. "Development and Optimisation of Novel
496   Polymeric Compositions for Sustained Release Theophylline Caplets (PrintCap) via FDM 3D
497   Printing." *Polymers (Basel)* 12 (1). https://doi.org/10.3390/polym12010027.
498   Teng, Jing, Simon Bates, David A. Engers, Kevin Leach, Paul Schields, and Yonglai Yang. 2010. "Effect
499   of Water Vapor Sorption on Local Structure of Poly(vinylpyrrolidone)." *Journal of
500   Pharmaceutical Sciences* 99 (9): 3815-3825.
501   https://doi.org/https://doi.org/10.1002/jps.22204.
502   Tian, Bin, Ling Zhang, Zhendong Pan, Jingxin Gou, Yu Zhang, and Xing Tang. 2014. "A comparison of
503   the effect of temperature and moisture on the solid dispersions: Aging and crystallization."
504   *International Journal of Pharmaceutics* 475 (1): 385-392.
505   https://doi.org/https://doi.org/10.1016/j.ijpharm.2014.09.010.
506   Ueda, Keisuke, Hitomi Okada, Zhijing Zhao, Kenjirou Higashi, and Kunikazu Moribe. 2020. "Application
507   of solid-state 13C relaxation time to prediction of the recrystallization inhibition strength of
508   polymers on amorphous felodipine at low polymer loading." *International Journal of
509   Pharmaceutics* 581: 119300. https://doi.org/https://doi.org/10.1016/j.ijpharm.2020.119300.
510   Vo, Anh Q., Jiaxiang Zhang, Dinesh Nyavanandi, Suresh Bandari, and Michael A. Repka. 2020. "Hot melt
511   extrusion paired fused deposition modeling 3D printing to develop hydroxypropyl cellulose
512   based floating tablets of cinnarizine." *Carbohydrate Polymers* 246: 116519.
513   https://doi.org/https://doi.org/10.1016/j.carbpol.2020.116519.

514   Wei, Can, Nayan G. Solanki, Jaydip M. Vasoya, Ankita V. Shah, and Abu T. M. Serajuddin. 2020.
515   "Development of 3D Printed Tablets by Fused Deposition Modeling Using Polyvinyl Alcohol as
516   Polymeric Matrix for Rapid Drug Release." *Journal of Pharmaceutical Sciences* 109 (4): 1558-
517   1572. https://doi.org/https://doi.org/10.1016/j.xphs.2020.01.015.
518   Xie, Tian, and Lynne S. Taylor. 2017. "Effect of Temperature and Moisture on the Physical Stability of
519   Binary and Ternary Amorphous Solid Dispersions of Celecoxib." *Journal of Pharmaceutical*
520   *Sciences* 106 (1): 100-110. https://doi.org/https://doi.org/10.1016/j.xphs.2016.06.017.
521   Zhang, Jiaxiang, Rishi Thakkar, Yu Zhang, and Mohammed Maniruzzaman. 2020. "Structure-Function
522   Correlation and Personalized 3D Printed Tablets using a Quality by Design (QbD) Approach."
523   *International Journal of Pharmaceutics*: 119945.
524   https://doi.org/https://doi.org/10.1016/j.ijpharm.2020.119945.
525

Fig. 1. TGA (A) thermographs for the impact of the storage condition (5 °C) on Eudragit EPO-based filament., (B) DSC thermographs for the impact of the storage condition (30 °C) on Eudragit EPO-based filament (filaments deformed and no further assessment was carried out after 1 month.

Fig. 2. TGA (A) and DSC (B) thermographs for the impact of the storage conditions on the Eudragit RL-based filament.

Fig. 3. TGA (A) and DSC (B) thermographs for the impact of the storage conditions (30 °C + 65% RH + Vac) on the Eudragit L100-55-based filaments.

Fig. 4. Representative TGA (A) and DSC (B) thermographs for the impact of the storage conditions (30 ºC + 65% RH + Vac) on the Eudragit S100-based filaments.

Fig. 5. TGA (A) and DSC (B) thermographs for the impact of the storage conditions on the HPC.SSL-based filaments.

Fig. 6. TGA thermographs for the impact of the storage conditions (5 °C) on the PVP-based filaments.

Fig. 7. XRPD data for the impact of the storage conditions on the Eudragit EPO (A), Eudragit RL (B), HPC.SSL (C) and PVP (D)-based drug loaded filament

**Fig. 8.** The impact of storage at 5 ^{O}C on the *in-vitro* release profile of theophylline from the PVP-based product.

Fig. 9. The impact of the storage conditions on the *in-vitro* drug release profile of theophylline from the Eudragit EPO-based 3D printed tablets.

Fig. 10. The impact of the storage conditions on the *in-vitro* release profile of theophylline from the Eudragit RL-based 3D printed tablets.